Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Harmony Biosciences Holdings (HRMY) Gross Profit (2020 - 2025)

Harmony Biosciences Holdings (HRMY) has disclosed Gross Profit for 6 consecutive years, with $175.2 million as the latest value for Q4 2025.

  • Quarterly Gross Profit rose 19.32% to $175.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $670.1 million through Dec 2025, up 20.11% year-over-year, with the annual reading at $670.1 million for FY2025, 20.11% up from the prior year.
  • Gross Profit hit $175.2 million in Q4 2025 for Harmony Biosciences Holdings, down from $179.8 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $179.8 million in Q3 2025 to a low of $49.3 million in Q1 2021.
  • Historically, Gross Profit has averaged $114.7 million across 5 years, with a median of $117.2 million in 2023.
  • Biggest five-year swings in Gross Profit: skyrocketed 201.02% in 2021 and later rose 11.95% in 2024.
  • Year by year, Gross Profit stood at $73.4 million in 2021, then soared by 38.19% to $101.4 million in 2022, then increased by 23.5% to $125.3 million in 2023, then rose by 17.24% to $146.9 million in 2024, then rose by 19.32% to $175.2 million in 2025.
  • Business Quant data shows Gross Profit for HRMY at $175.2 million in Q4 2025, $179.8 million in Q3 2025, and $162.3 million in Q2 2025.